Loading stock data…
$0.87+0.02 (+2.34%)
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States.
60 Degrees Pharmaceuticals, Inc. in the Healthcare sector is trading at $0.87 with a market capitalization of $3M. Wall Street consensus targets $3.70 (1 analysts), implying a +325.2% move over the next 12 months. The stock is currently near its 52-week low of $0.81, remaining 51.7% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $207,898↑ | $162,092↓ | $303,385↓ | $437,602↑ | $100,932 |
| Gross Profit | $56,798↓ | $76,377↓ | $182,703↑ | -$100,088↓ | $50,881 |
| Operating Income | -$2.27M↓ | -$2.09M↓ | -$1.92M↑ | -$2.33M↓ | -$1.61M |
| Net Income | -$2.26M↓ | -$2.09M↓ | -$1.44M↑ | -$2.32M↓ | -$1.73M |
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention...